FDA Approves First New Influenza Drug in 20 Years

Share this content:
FDA Approves First New Influenza Drug in 20 Years
FDA Approves First New Influenza Drug in 20 Years

WEDNESDAY, Oct. 24, 2018 (HealthDay News) -- For the first time in nearly two decades, the U.S. Food and Drug Administration has approved a new type of antiviral influenza drug.

The single oral dose of Xofluza (baloxavir marboxil) is for the treatment of uncomplicated influenza in patients aged 12 years and older who have had symptoms for no more than 48 hours. When used within 48 hours of getting sick with influenza, antiviral drugs can reduce symptoms and duration of the illness, according to the FDA.

The drug's approval was based on two randomized controlled trials of 1,832 patients who received Xofluza, a placebo, or another antiviral influenza treatment within 48 hours of experiencing symptoms. In both trials, patients who received Xofluza had quicker relief of symptoms than those who received placebo. In the second trial, the time to symptom relief was the same for patients who received Xofluza and those who received the other antiviral treatment, according to the FDA. The most common side effects in patients taking Xofluza were diarrhea and bronchitis.

"With thousands of people getting the flu every year, and many people becoming seriously ill, having safe and effective treatment alternatives is critical," FDA Commissioner Scott Gottlieb, M.D., said in a statement. "This novel drug provides an important, additional treatment option."

Gottlieb noted, "While there are several FDA-approved antiviral drugs to treat flu, they're not a substitute for yearly vaccination."

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Progress in HIV Prevention Has Stalled in the United States

CDC: Progress in HIV Prevention Has Stalled in ...

Agency says effective HIV prevention, treatment not reaching those who could most benefit

AAAAI: Egg Oral Immunotherapy Shows Sustained Benefit in Children

AAAAI: Egg Oral Immunotherapy Shows Sustained Benefit in ...

All children with sustained unresponsiveness ingested concentrated and baked egg

Prenatal Vitamin Intake in Early Pregnancy May Cut Autism Risk

Prenatal Vitamin Intake in Early Pregnancy May Cut ...

ASD risk down for children whose mothers took prenatal vitamins during first month of pregnancy

is free, fast, and customized just for you!




Already a member?

Sign In Now »